The structural protein VP24 of Ebola virus (EBOV) is a determinant of virulence in rodent models and possesses an interferon antagonist function. In this study, we investigate the role of VP24 in EBOV replication using RNA interference by small interfering RNA to knock down the expression of this protein in virus-infected cells. We reveal that VP24 is required for assembly of viral nucleocapsids and that silencing of VP24 expression prevents the release of EBOV.
The structural protein VP24 of Ebola virus (EBOV) is a determinant of virulence in rodent models and possesses an interferon antagonist function. In this study, we investigate the role of VP24 in EBOV replication using RNA interference by small interfering RNA to knock down the expression of this protein in virus-infected cells. We reveal that VP24 is required for assembly of viral nucleocapsids and that silencing of VP24 expression prevents the release of EBOV.
Ebola virus (EBOV) and Marburg virus are members of the family Filoviridae within the order Mononegavirales and, on the basis of substantial biological differences, have been separated into the genera Ebolavirus and Marburgvirus, respectively [1] . EBOV infections can cause a severe hemorrhagic fever in both monkeys and humans, with fatality rates reaching up to 90%. EBOV pathogenesis is associated with high viral loads, involvement of multiple organs, the capacity to greatly impair immune responses, and extensive coagulopathy [2, 3] . Currently there are no vaccines or treatments available for human use despite promising studies using recombinant technologies [4, 5] . The structural protein VP24 is encoded by the sixth of 7 linearly arranged genes. VP24 has been demonstrated to interfere in the interferon signaling pathway by interacting with karyopherin-a and blocking STAT1 translocation into the nuclei [6] [7] [8] . VP24 was also shown to play a role in EBOV virulence in rodents [9, 10] . It had been speculated that in a mice model this role could rely on VP24's ability to counteract the interferon system [10] . There is also evidence that this protein can affect the transcription and replication of an EBOV minigenome [11, 12] and, when transiently expressed together with NP and VP35, is involved in the formation of viral nucleocapsids [13] [14] [15] . In contrast to VP24 of EBOV, Marburg virus VP24 does not impair interferon signaling [16] but participates in the formation of Finfectious particles during virus replication in vitro [17] . Silencing the expression of Marburg virus VP24 by means of RNA interference in infected cells drastically reduces the release of virus particles [17] . In this study, we address the function of VP24 in the replication of EBOV by reducing its expression in the virus-infected cells using VP24-specific small interfering RNAs (siRNAs) and by a reverse genetics approach in which recombinant constructs defective in VP24 expression have been generated.
MATERIALS AND METHODS

Cells and Viruses
Vero E6 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100 lg/mL streptomycin (Invitrogen) at 37°C. The cells were grown for 24 hours to a confluence of approximately 60%.
Recombinant Zaire EBOV strain Mayinga was generated as described previously [18] . Virus was amplified by 2 passages in Vero E6 cells, aliquoted, and kept at 280°at the Jean Mérieux BSL-4 Laboratory, Lyon, France. Virus titers were estimated by determination of the median tissue culture infective dose on Vero E6 cells.
Recovery of Recombinant VP24-Deficient EBOVs
Previously, we established a full-length cDNA clone of the Zaire EBOV, strain Mayinga [18] . Using the intermediate plasmid pKSS25, we deleted the sequence coding for the VP24 gene (nucleotides 9883-11499; numbers refer to the positive-sense antigenome) without altering VP30 gene transcription termination and L gene transcription initiation signals. Alternatively, to silence VP24 expression, a set of translational stop codons were introduced at positions 10351, 10384, 10387, and 10504 by site-directed mutagenesis. Modified cDNA fragments were used to reconstitute a ''full-length'' cDNA of EBOV as previously described [18] . Rescue attempts were performed in 3 independent experiments under BSL-4 conditions. In a set of separate experiments, the recovery of VP24-deficient EBOV constructs was performed using BHKT7 cells cotransfected with a plasmid (phCMV-EBOV/VP24) expressing wild-type VP24 of EBOV.
siRNA-Mediated Knockdown of VP24 Expression
VP24-specific siRNAs (siRNA VP24 ) were designed using BLOCK-it RNAi designer (Invitrogen) and synthetized as duplexes by Invitrogen. The VP24 RNA sequences specifically targeted were [GGGUUGUCUUAAGCGACCUCUGUAA] (siRNA VP24 -1, nucleotides 10403-10427) and [GGUGGAAG-GUUUAUUGGGCUGGUAU] (siRNA VP24 -2, nucleotides 10454-10478). A control siRNA (siRNA CT ) with no substantial homology with any known human or viral sequence was used as a nonspecific control (stealth RNAi negative control duplexes medium GC, Invitrogen). Vero E6 cells were transfected with 50 pmol of each siRNA using Lipofectamine RNAi Max (Invitrogen). The cells were washed in serum-free medium 6 hours after transfection and then incubated for 1 hour with serum-free medium containing EBOV at a multiplicity of infection of 1. After 1 hour incubation, the cells were washed and incubated with DMEM containing 2.5% FCS and incubated at 37°C under 5% CO 2 . The cells and culture supernatants were harvested separately at days 1 and 2 after infection and analyzed for the presence of nucleoprotein (NP), VP40, glycoprotein (GP), and VP24 by Western blotting using appropriate antibodies.
Western blotting. Western blot analysis was performed as previously described [19] . To reveal viral proteins NP, VP40, GP, and VP24 we used mouse monoclonal antibodies against NP (in-house produced; dilution, 1:2000), mouse monoclonal anti-VP40 antibodies (9B12, a gift from Winfried Weissenhorn, European Molecular Biology Laboratory; dilution, 1:2000), a polyclonal rabbit serum against GP (in-house produced; dilution, 1:1000), a polyclonal rabbit serum against VP24 (in-house produced; dilution, 1:4000), and polyclonal goat anti-actin antibodies (sc-1616, Santa-Cruz). Horseradish peroxidase-coupled goat anti-mouse, goat anti-rabbit, and rabbit anti-goat antibodies (Dako; dilution, 1:20,000) were used as secondary antibodies. Detection of the protein bands was performed using SuperSignal West Dura Substrate (Pierce) and Kodak Biomax MR films.
Electron microscopy. EBOV-infected Vero E6 cells were fixed in phosphate-buffered saline (PBS) containing 4% paraformaldehyde-2% glutaraldehyde (Sigma) for 3 weeks. After fixation, the cells were washed in PBS and postfixed in PBS containing 1% osmium tetroxide. Cells were then dehydrated and embedded in EPON resin. Ultrathin sections were prepared using an Ultracut E microtome (Reichert) and a diamond knife (Diatome) and then stained with uranyl acetate and lead citrate. The samples were imaged using a CM120 electron microscope (Philips).
RESULTS AND DISCUSSION
Our multiple attempts to generate VP24-deficient recombinant EBOVs using a reverse genetics system [18] failed, suggesting that VP24 is essential for virus replication. Moreover, our efforts to recover such viruses by providing VP24 expressed from a transfected plasmid in trans were also unsuccessful, indicating that a finely balanced VP24 expression might be necessary (data not shown). Interestingly, however, recombinant EBOVs deficient in VP30 synthesis have recently been successfully rescued from cells constitutively expressing this protein [20] . It appears that constitutive expression of VP30, which is a positive regulator of EBOV transcription [21] [22] [23] , supports replication of VP30-deficient EBOVs. On the other hand, observations obtained with a minigenome system [11, 12] indicate that VP24 may function as a negative regulator of replication and transcription, and this could explain to a certain degree the disappointing results with EBOV VP24 provided in trans. Our attempts to establish a cell line constitutively expressing VP24 also failed, probably as a result of as yet undefined cytotoxic properties of this protein (data not shown).
In this study, to investigate the role of VP24 in EBOV replication, we finally used RNA interference by siRNA to knock down the expression of this protein in virus-infected cells. Two VP24-specific siRNA duplexes directed against different regions of the VP24 gene were utilized to specifically decrease VP24 expression. The siRNAs were transfected in parallel with a negative control siRNA CT into Vero E6 cells, which were subsequently infected with EBOV at a multiplicity of infection of 1. GP, VP24, and actin were analyzed by Western blotting using appropriate antibodies (Figure 1) . Two days after infection, the levels of actin in cells transfected by siRNAs were similar, indicating that VP24-specific siRNAs did not induce any additional cytotoxic effects. On the first day after infection, the levels of viral protein synthesis were apparently low, because we had difficulties in detecting viral proteins in the cells and failed to observe virus release into the culture supernatants. Indeed, only 3 viral proteins were detected in the cells: NP, GP1, and VP24. As shown in Figure 1 , transfection of cells with siRNA VP24 resulted in a decrease of VP24 synthesis, compared with cells treated with siRNA CT . Of the 2 VP24-specific siRNAs used in this study, siRNA VP24 -2 had the strongest effect on VP24 expression. Levels of viral proteins substantially increased on day 2 after infection, and the release of EBOV was detected as judged by the appearance of NP in the culture supernatants. Both VP24-specific siRNAs induced a decrease in EBOV release that correlated with decreased VP24 levels in the cells. The decrease in EBOV release was accompanied by accumulation of viral proteins in the cells and was caused by VP24 silencing. This was evident in particular on the first day after infection, when the levels of NP and GP1 in cells treated with VP24-specific siRNAs were notably higher, compared with those in cells transfected with siRNA CT (Figure 1 , left panel). As shown in Figure 1 (right panel) , the transfection of cells with siRNA VP24 appears to have led to a decrease in the synthesis of other viral proteins in addition to a decrease in VP24 expression, compared with transfection with siRNA CT . However, this difference could be explained by the fact that at a multiplicity of infection of 1, it is unlikely that all the cells were simultaneously infected, thus causing a second round of infections by the virions released from initially infected cells. If this is the case, the reduction in virus release would lead to differences between control and VP24-specific siRNAs in the number of infected cells and in the amounts of synthesized viral proteins. To estimate the difference in amounts of viral proteins synthesized in the cells, it should be noted that 1/30 of lysed cells and 1/150 of culture supernatants were loaded onto the polyacrylamide gels (Figure 1) . Taken together, the data obtained indicate that silencing of VP24 expression results in defects of virus release from infected cells. Our results are in accordance with findings by Bamberg et al, who investigated the role of VP24 from the closely related Marburg virus using a similar approach [17] . The authors speculated that VP24 of Marburg virus is involved in the assembly and transport of viral nucleocapsids and may also be important during the interaction between nucleocapsids and the virus budding sites at the plasma membrane.
Up to now, the role of VP24 in EBOV nucleocapsid assembly has only been addressed using transient expression systems. It was shown that the coexpression of NP, VP24, and VP35 is indispensable for the formation of nucleocapsid-like structures that are morphologically indistinguishable from nucleocapsids in virus-infected cells [13-15, 24, 25] , whereas expression of NP alone results only in the formation of thin tubular structures [25] . To investigate the effect of the knockdown of VP24 on nucleocapsid assembly, we used electron microscopy. For this purpose, Vero E6 cells were transfected with either siRNA CT or siRNA VP24 -2 and were subsequently infected with EBOV as aforementioned. At day 2 after infection, the cells were fixed and subjected to thin section electron microscopy ( Figure 2) . In siRNA CT -treated cells, large cytoplasmic inclusions, a hallmark of EBOV infection [14, 26] consisting of numerous viral nucleocapsids, were detected. Remarkably, relatively huge cytoplasmic inclusions were observed also in siRNA VP24 -treated cells, which, however, contained few or no typical viral nucleocapsids. On the contrary, these ''atypical'' inclusions were composed of structures resembling the tubes formed by NP expressed without other viral proteins required for nucleocapsid assembly [14] . Interestingly, formation of similar structures was Figure 2 . VP24 of Ebola virus is required for nucleocapsid formation. Vero E6 cells were transfected with the indicated small interfering RNAs (siRNAs) and then infected with Ebola virus as described. Infected cells were collected at day 2 after infection, fixed, and subjected to thin section electron microscopy. Samples were observed using a Phillips CM120 electron microscope at 80 kV. Bars on the left-hand panels denote 1 lm, and the bars on the right-hand panels denote 500 nm. observed when EBOV NP was coexpressed with the VP24 mutants defective in nucleocapsid formation [11, 15] .
In conclusion, the data obtained provide factual evidence that VP24 is required and plays a critical role in nucleocapsid assembly in EBOV-infected cells. Although VP24 of the Ebola and Marburg viruses differ in respect to functioning as antagonists of interferon signaling [16] , both proteins appear to play similar roles during assembly of viral nucleocapsids. Because nucleocapsid assembly is a key event during the replication of filoviruses, VP24 represents an important target for the development of antiviral treatments.
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